Venglustat + Placebo
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Kidney, Autosomal Dominant
Conditions
Polycystic Kidney, Autosomal Dominant
Trial Timeline
Oct 4, 2018 → Aug 3, 2021
NCT ID
NCT03523728About Venglustat + Placebo
Venglustat + Placebo is a phase 2/3 stage product being developed by Sanofi for Polycystic Kidney, Autosomal Dominant. The current trial status is terminated. This product is registered under clinical trial identifier NCT03523728. Target conditions include Polycystic Kidney, Autosomal Dominant.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03523728 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Polycystic Kidney, Autosomal Dominant